Yubo International Biotech Ltd
Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing) Limited and related contractual arrangements. The business focuses on endometrial stem cell research and application, and markets a mix of healthcare products and stem cell-related services under the VIVCELL brand.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueResearch, testing, and consulting services centered on endometrial stem cells.
Consumer healthcare products positioned for respiratory wellness and related care.
Beauty and personal care products sold under the VIVCELL brand.
Functional beverage products marketed as part of the wellness portfolio.
Male and female personal care products tied to the company’s consumer health offering.
Consulting services related to health management and cell-related wellness.
Customers
The company sells to a small number of customers, with historical revenue concentrated in a limited customer base in China. Its offerings appear to serve both consumer wellness buyers and customers seeking cell testing or health management services. The concentration disclosed in filings suggests that a few counterparties can materially affect near-term sales.
Buy branded healthcare, skincare, hair care, beverage, and personal care products for everyday use.
Use cell testing and health management consulting tied to the company’s stem cell platform.
Purchase product inventory or act as channel partners for the VIVCELL brand in China.
Strategy
The company’s strategy is centered on building its stem cell platform while commercializing a broader VIVCELL-branded wellness portfolio. It also relies on maintaining the licenses, approvals, and contractual structure needed to operate in China through a VIE. Customer concentration and product breadth suggest a need to broaden the commercial base while keeping the core technology narrative intact.
The company’s differentiation depends on its endometrial stem cell research and related services.
Product sales provide a broader market beyond specialized stem cell services.
The business depends on PRC licenses, approvals, and contractual arrangements with the VIE.
Geography
Yubo International Biotech is a U.S. holding company, but its operating activities are centered in Beijing, China through a VIE structure. The filings indicate that day-to-day business is conducted in China, making the company dependent on Chinese licenses, approvals, and operating conditions. This structure creates a clear geographic split between the listed parent and the operating business.
Risks
The company faces concentration risk because historical revenue has come from a limited number of customers, and recent periods disclosed no sales. Its China-based operating model also exposes it to PRC regulatory, licensing, and VIE-structure risks, while the consumer health and biotech mix adds product, compliance, and execution risk. As a small operating platform, it is also vulnerable to demand volatility and dependence on a narrow set of products and counterparties.
Historical revenue has been generated from a limited number of customers, increasing dependence on a few buyers.
Exposure: One customer accounted for 92% of sales in a prior quarter
The business requires PRC licenses and approvals to operate and is subject to local regulatory oversight.
Exposure: Beijing operating entity and PRC permits
The listed parent does not directly own the PRC operating company, so control depends on contractual arrangements.
Exposure: Yubo Beijing VIE structure
Healthcare, personal care, and food-related products can face quality, labeling, and regulatory compliance issues.
Exposure: Food Operation License Permit and medical distribution filing
Accounting
Judgemental itemsManagement must estimate fair values for certain assets and liabilities, which can materially affect reported results.
Impact: Valuation assumptions can change earnings and balance sheet values
The holding-company structure and share count dynamics can affect EPS presentation.
Impact: Dilution and share structure may distort per-share comparability
The company relies on estimates for obligations that are not fully known at period end.
Impact: Expense recognition may shift between periods
Control is based on contractual arrangements rather than direct equity ownership.
Impact: Consolidation judgments affect what assets, liabilities, and revenue are reported
Similar listed companies
Publicly listed companies with a comparable business focus.
International Stem Cell CORP
ISCO · Pharmaceutical Preparations
INVO Fertility, Inc.
IVF · Surgical & Medical Instruments & Apparatus
SL Science Holding Ltd
SLBT · Biological Products, (No Diagnostic Substances)
SL Science Holding Ltd is a U.S.-listed biotechnology and biological products company based in Taipei, Taiwan, operating through its SL Bio business.
Jingbo Technology, Inc.
SVMB · Services-Prepackaged Software
YD Bio Ltd
YDES · Services-Medical Laboratories
YD Bio Ltd is a U.S.-anchored biotechnology and medical-laboratory services company with operations spanning regulated diagnostics, life science clinical…
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Last updated: 24/09/2026